8-K
filed April 21, 2023, 7:59 PM ET
ticker PSTV
CIK 0001095981
other material
confidence high
sentiment neutral
materiality 0.65
Plus Therapeutics stockholders approve reverse stock split authorization at annual meeting
PLUS THERAPEUTICS, INC.
- Reverse stock split approved; ratio of 1:3 to 1:15 to be set by board at a later date.
- All six director nominees elected, including Marc Hedrick and Howard Clowes.
- BDO USA ratified as independent auditor for 2023; say-on-pay passed with 4.58M for.
- Stockholders favored one-year frequency for future advisory votes on executive compensation.
- Amended 2020 Stock Incentive Plan approved; preferred stock (50M votes) voted proportionally on split.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
PLUS THERAPEUTICS, INC. shareholders approved Non-binding advisory vote on the compensation of the Company’s named executive officers at the 2023-04-20 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-04-20
Exact text from the filing
3. Proposal to provide a non-binding advisory vote on the compensation of the Company’s named executive officers: For Against Abstain 4,580,421 1,735,989 179,468
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
PLUS THERAPEUTICS, INC. shareholders approved Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the outstanding shares of the Company’s common stock, at a ratio of not less than 1-for-3 and not greater than 1-for-15 at the 2023-04-20 meeting.
- Proposal
- reverse split
- Outcome
- passed
- Meeting
- 2023-04-20
Exact text from the filing
5. Proposal to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of our issued and outstanding shares of common stock, at a specific ratio, ranging from one-for-three (1:3) to one-for-fifteen (1:15): For Against Abstain 52,798,957 12,179,757 517,698
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
PLUS THERAPEUTICS, INC. shareholders approved Election of six directors to serve until the 2024 annual meeting or until their successors are duly elected and qualified at the 2023-04-20 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-04-20
Exact text from the filing
1. Proposal to elect six directors to serve until the 2024 annual meeting or until their successors are duly elected and qualified: For Withheld Broker Non-Votes Howard Clowes 5,306,629 1,189,249 9,000,533 An van Es-Johansson 5,387,484 1,108,394 9,000,533 Richard J. Hawkins 5,364,397 1,131,481 9,000,533 Marc H. Hedrick, M.D. 5,700,185 795,693 9,000,533 Robert Lenk 5,308,285 1,187,593 9,000,533 Greg Petersen 5,675,200 820,678 9,000,533
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
PLUS THERAPEUTICS, INC. shareholders approved Ratification of the appointment of BDO USA, LLP as the Company’s independent auditors for the 2023 fiscal year at the 2023-04-20 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-04-20
Exact text from the filing
2. Proposal to ratify the appointment of BDO USA, LLP as the Company’s independent auditors for the 2023 fiscal year: For Against Abstain 14,681,590 617,972 196,849
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
PLUS THERAPEUTICS, INC. shareholders approved Non-binding advisory vote on the frequency of holding future non-binding advisory votes on executive officer compensation at the 2023-04-20 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2023-04-20
Exact text from the filing
4. Proposal to provide a non-binding advisory vote on the frequency of holding future non-binding advisory votes on executive officer compensation: One Year Two Years Three Years Abstain 5,695,824 105,972 401,874 292,208
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
PLUS THERAPEUTICS, INC. shareholders approved Approval of the third amendment and restatement of the Company’s 2020 Stock Incentive Plan at the 2023-04-20 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-04-20
Exact text from the filing
6. Proposal to approve the third amendment and restatement of the Company’s 2020 Stock Incentive Plan: For Against Abstain 4,279,475 2,112,637 103,766
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.